Table 1 The role of YTHDF2 in cancers
Cancer type | Expression | Role | Function in cancer | Molecular mechanism | Year |
|---|---|---|---|---|---|
GC | Upregulated | Oncogene | Facilitating proliferation, invasion and migration | Mediating the degradation of PTEN mRNA to activate PI3K/AKT signaling pathway | 2019 |
Downregulated | Tumor suppressor | Inhibiting proliferation, migration and prolonging OS | Regulating FOXC2 Signaling | 2019, 2020 | |
CRC | Upregulated | Oncogene | Facilitating proliferation | Regulated by miR-145 and regulating Wnt/β-catenin pathway | 2021 |
Downregulated | Tumor suppressor | Restraining proliferation and metastasis | Modulating the degradation of XIST | 2020 | |
– | Tumor suppressor | Prolonging OS | – | 2020 | |
Liver cancer | Upregulated | Oncogene | Enhancing proliferation | Regulated by miR-145 | 2017 |
– | Mediating the degradation of SOCS2 mRNA | 2018 | |||
Shortening OS | – | 2020 | |||
Promoting liver cancer stem cell phenotype and metastasis | Mediating the translation of OCT4 | 2020 | |||
Downregulated | Tumor suppressor | Repressing proliferation and growth | Regulating MAPK/ERK signaling | 2018 | |
Suppressing proliferation, metastasis, tumor inflammation and vascular abnormalities Prolonging OS and RFS | Mediating the degradation of IL11 and serpin E2 mRNAs | 2019 | |||
PC | Upregulated | Oncogene and tumor suppressor | Enhancing proliferation and inhibiting invasion, adhesion, migration and EMT | Regulating Hippo signaling | 2017 |
– | Oncogene | – | Mediating the degradation of PER1 mRNA | 2020 | |
– | Tumor suppressor | Inhibiting proliferation and migration | Modulating the degradation of PIK3CB mRNA to inhibit activation of PI3K/AKT signaling pathway | 2020 | |
Lung cancer | Upregulated | Oncogene | Accelerating proliferation and metabolism defect | Mediating the translation of 6PGD to regulate pentose phosphate pathway | 2019 |
– | Prolonging OS and RFS | – | 2020 | ||
Oncogene | Facilitating proliferation, reducing apoptosis, but prolonging OS and RFS | – | 2021 | ||
Oncogene | Enhancing cell growth, colony formation and migration | Regulating Wnt/β-catenin pathway | 2021 | ||
Downregulated | Tumor suppressor | Suppressing proliferation, invasion, migration and EMT and prolonging OS | Regulating Hippo signaling | 2020 | |
Leukemia | Upregulated | Oncogene | Facilitating proliferation, restraining apoptosis and marrow reconstitution | Regulating TNF signaling | 2019 |
Enhancing proliferation, suppressing apoptosis | Regulating TNF signaling | 2021 | |||
PTCL-NOS | – | Oncogene | Shortening OS | – | 2019 |
PCa | Upregulated | Oncogene | Promoting proliferation, migration and colony formation, suppressing apoptosis | Mediating the degradation of LHPP and NKX3–1 mRNAs | 2020 |
Enhancing proliferation, migration and invasion, reducing apoptosis | Regulated by miR-495 and mediating the degradation of MOB3B mRNA | 2020 | |||
Bladder cancer | Upregulated | Oncogene | Facilitating migration | Mediating the degradation of SETD7 and KLF4 mRNAs | 2020 |
ccRCC | Downregulated | Tumor suppressor | Prolonging OS | – | 2020 |
CC | – | Oncogene | Promoting proliferation, migration and invasion | Modulating the degradation of GAS5 mRNA | 2019 |
Ovarian cancer | Upregulated | Oncogene | Promoting proliferation and colony formation, inhibiting apoptosis | Mediating the degradation of BMF mRNA | 2021 |
Breast cancer | Upregulated | Oncogene | Facilitating proliferation, inhibiting apoptosis and cell cycle arrest | Modulating the degradation of PRSS23 mRNA | 2021 |
Osteosarcoma | – | Tumor suppressor | Inhibiting proliferation and metastasis | Regulating the degradation of PVT1 mRNA | 2020 |
Melanoma | Upregulated | Oncogene | Promoting proliferation, migration and colony formation | Mediating the degradation of PER1 and TP53 mRNAs | 2021 |
Downregulated | Tumor suppressor | Suppressing proliferation and migration | Regulating the degradation of PD-1, CXCR4, and SOX10 mRNAs | 2019 | |
GBM | Upregulated | Oncogene | Maintaining glioblastoma stem cells | Modulating the stability of MYC and VEGFA mRNAs | 2020 |
Facilitating proliferation, invasion, and tumorigenesis | Mediating the degradation of LXRA and HIVEP2 mRNAs | 2021 | |||
Promoting proliferation and migration | Regulating the degradation of UBXN1 mRNA | 2021 | |||
HNSCC | Upregulated | Oncogene | Shortening OS | – | 2020 |